Combined aPproach to treatment using ranibizumab and efalizumab for diabetic macular edema study: The CAPTURE DME study
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 02 Sep 2016
At a glance
- Drugs Efalizumab (Primary) ; Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Acronyms CAPTURE DME
- 10 Jun 2017 Biomarkers information updated
- 30 Jan 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 04 Jun 2008 New trial record.